Lithium succinate

Lithium succinate
Clinical data
Other names	Lithium succinate dibasic
AHFS/Drugs.com	Monograph
ATC code	D11AX04 (WHO) ;
Identifiers
	IUPAC name Dilithium butanedioate;
CAS Number	29126-50-9;
PubChem CID	10197702;
DrugBank	DB14508 ;
ChemSpider	8373202 ;
UNII	MD64P82Y28;
ChEMBL	ChEMBL3707288;
ECHA InfoCard	100.163.153
Chemical and physical data
Formula	C4H4Li2O4
Molar mass	129.95 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES [Li+].[Li+].[O-]C(=O)CCC([O-])=O;
	InChI InChI=1S/C4H6O4.2Li/c5-3(6)1-2-4(7)8;;/h1-2H2,(H,5,6)(H,7,8);;/q;2*+1/p-2 ; Key:WAHQBNXSPALNEA-UHFFFAOYSA-L ;
	(verify)

Lithium succinate (C₄H₄Li₂O₄), the dilithium salt of succinic acid, is a drug used in the treatment of seborrhoeic dermatitis^[1] and proposed for the treatment of anogenital warts.^[2]

References

^ Leeming JP (1993). "Use of topical lithium succinate in the treatment of seborrhoeic dermatitis". Dermatology. 187 (2): 149–50. doi:10.1159/000247228. PMID 8358107.
^ Ward KA, Armstrong KD, Maw RD, Winther MD, Gilburt SJ, Dinsmore WW (1997). "A pilot study to investigate the treatment of anogenital warts with Topical Lithium Succinate cream (8% lithium succinate, 0.05% zinc sulphate)". International Journal of STD & AIDS. 8 (8): 515–7. doi:10.1258/0956462971920677. PMID 9259500. S2CID 23095115.

"Lithium succinate". Drug Information Portal. U.S. National Library of Medicine.

This dermatologic drug article is a stub. You can help Wikipedia by expanding it.